NEWS
Semaglutide Rewires Kidney Filters in Diabetic Kidney Disease
Semaglutide cut urine albumin 40% in diabetic kidney disease, but a 106-person trial missed its main kidney MRI goals, limiting reversal claims.
Semaglutide cut urine albumin 40% in a 52-week trial of 106 people with type 2 diabetes and chronic kidney disease. The same study’s main kidney MRI goals did not move.
REMODEL, published October 1, 2026 in Nature Medicine, was built to explain a larger outcome trial, not to rerun it. The tissue work points at quieter glomerular endothelium in diabetic kidney disease, the group that still drives kidney failure. It does not show that every form of chronic kidney disease can be walked back.
REMODEL Was a Mechanism Trial, Not a Repeat of FLOW
Katherine Tuttle, a nephrologist at the University of Washington’s Providence Medical Research Center in Spokane, and colleagues ran a 52-week randomized trial of semaglutide 1 mg once a week against placebo. They enrolled adults with type 2 diabetes and chronic kidney disease at 28 sites in 8 countries between April 2021 and October 2023. Novo Nordisk A/S funded the work. The trial is registered as NCT04865770.
Randomization was 2 to 1, with 71 people on semaglutide and 35 on placebo. Mean age was 65.3 years, and 25 of the 106 were women. Mean eGFR, a blood estimate of how much the kidneys filter, sat at 51.1 ml per minute per 1.73 m2. Median urine albumin-to-creatinine ratio, or UACR, was 187.3 mg/g. Almost everyone already took a renin-angiotensin blocker (105 of 106). An SGLT2 inhibitor, another kidney-protective diabetes drug, was already on board for 42 of 106.
FLOW, the 2024 outcomes trial in the New England Journal of Medicine, had already tested the same weekly 1 mg shot in 3,533 people with type 2 diabetes and chronic kidney disease. Over a median 3.4 years, semaglutide cut the risk of a composite of major kidney decline, kidney failure, or death from kidney or heart causes by 24% (331 events versus 410; hazard ratio 0.76). REMODEL recruited a similar group and then looked inside the organ, with kidney MRI in the full cohort, paired biopsies in 33 people, single-nucleus RNA sequencing in 22, and spatial transcriptomics in 13.
The Scans That Did Not Move
The coprimary MRI outcomes were oxygenation by R2*, global kidney perfusion, and T1 mapping as a stand-in for tissue inflammation. After 52 weeks, none of those three differed from placebo at the trial’s statistical threshold. Cortical oxygenation was a little better on paper (estimated treatment ratio 0.98), and global perfusion was a little higher (1.10), but those gaps did not clear the bar the protocol set.
That miss is the brake on any claim that the filters were simply switched back on. Secondary MRI told a narrower story. Renal artery resistive index fell (estimated treatment ratio 0.96, P=0.008), a sign of lower resistance in the kidney’s arteries. Cortical apparent diffusion coefficient rose (1.05, P=0.005), which the authors read as slower fibrosis, because scarred tissue restricts how water moves. Mean arterial flow itself did not change.
REMODEL RESULTS AT 52 WEEKS
| Measure | Semaglutide vs placebo | Role in the trial |
|---|---|---|
| Oxygenation (R2*) | No significant change (ETR 0.98) | Coprimary MRI |
| Global kidney perfusion | No significant change (ETR 1.10) | Coprimary MRI |
| T1 mapping (inflammation stand-in) | No significant change | Coprimary MRI |
| Renal artery resistive index | ETR 0.96, P=0.008 | Secondary MRI |
| Cortical ADC (fibrosis marker) | ETR 1.05, P=0.005 | Secondary MRI |
| Urine albumin-to-creatinine ratio | 40% lower (ETR 0.60, P=0.008) | Exploratory clinical |
| Perirenal fat volume | 25% lower (ETR 0.75, P=0.027) | Exploratory MRI |
| Renal sinus fat volume | 13% lower (ETR 0.87, P=0.012) | Exploratory MRI |
Fat around the kidney fell harder than weight on the scale. Perirenal fat was 25% lower than placebo, sinus fat 13% lower, while body weight differed by 4.45 kg, about 5% of the 89.6 kg baseline. HbA1c fell 0.88 percentage points. Blood pressure did not separate from placebo. Location of the fat loss may matter more than the total, the way fat around the heart does in cardiac disease, though REMODEL did not prove that path caused the kidney result.
What Changed in the Kidney’s Filters?
UACR fell 40% on semaglutide compared with placebo (P=0.008). High albumin in urine is an early sign that the glomerulus, the tuft of tiny vessels that starts filtration, is leaking. Twenty-four-hour urine creatinine clearance, a secondary clinical measure, was 12 ml per minute higher (P=0.038). Creatinine-based eGFR was 3.4 ml per minute per 1.73 m2 higher, but that confidence interval ran from -0.2 to 6.9 and did not meet the usual threshold.
In the 33-person biopsy group (22 on semaglutide, 11 on placebo), the fractional intimal area of the most diseased arterioles was 10% lower versus placebo (P=0.032). Periglomerular mononuclear and lymphocytic infiltrate, present at baseline, lessened after 52 weeks on the drug. Glomerular basement-membrane thickness, glomerular volume, and mesangial expansion trended lower and were not the trial’s main test.
Single-nucleus work pointed at glomerular endothelial cells, the lining of those filter vessels. Genes tied to metabolic stress and inflammation turned down, and spatial maps showed fewer immune cells sitting next to that lining. Before treatment, Tuttle said, the vessels and immune cells were sending inflammatory signals back and forth.
After semaglutide, the immune cells went quiet, silencing the messages that ramp up harmful inflammation.
Katherine Tuttle, nephrologist, University of Washington Providence Medical Research Center
Susan Quaggin, a nephrologist at Northwestern University Feinberg School of Medicine who was not on the trial, said the pattern fits a direct effect on the kidney’s blood vessels, on top of the drug’s known anti-inflammatory action. GLP-1 receptors have been found in preglomerular vessels, efferent arterioles, and artery smooth muscle in human, monkey, and rodent kidneys, which is one reason a metabolic shot can have a local vascular read-out.
The Dialysis Population This Drug Can Reach
Chronic kidney disease affects nearly 800 million people, and it develops in 40% of those living with type 2 diabetes, making diabetes the leading cause of kidney failure worldwide, the REMODEL authors wrote. That is the population FLOW enrolled, and it is the population whose tissue REMODEL sampled. Hypertensive kidney disease, IgA nephropathy, and other forms were not the test.
In the United States, 131,564 people started ESKD treatment in 2023, according to figures drawn from the United States Renal Data System 2025 Annual Data Report. At the end of that year, 831,192 people were receiving treatment for kidney failure, about 67% on dialysis and 33% living with a transplant. In 2024, 22,916 people on dialysis received a kidney transplant, and 273,041 people were living with a transplant at year’s end.
KIDNEY FAILURE IN THE UNITED STATES
- New cases, 2023: 131,564 people started treatment for end-stage kidney disease.
- Living with kidney failure, 2023: 831,192 people were on dialysis or had a transplant at year end.
- Share on dialysis: About 67% of that treated group, with 33% living with a transplant.
- Transplants from dialysis, 2024: 22,916 people on dialysis received a kidney.
FLOW did not turn off dialysis. Kidney replacement therapy occurred in 4.9% of the semaglutide group and 5.7% of the placebo group, a gap that did not stand on its own as a win. The composite still moved because fewer people lost half their eGFR or died of heart disease (cardiovascular death hazard ratio 0.71; death from any cause 20% lower, hazard ratio 0.80; major heart events 18% lower, hazard ratio 0.82). Annual eGFR decline was 1.16 ml per minute per 1.73 m2 less steep on the drug. The second-order read is slower: a weekly shot that trims events in diabetic kidney disease changes how many people still arrive at a chair, not whether chairs disappear.
January 2025 Gave Ozempic a Kidney Claim
On January 28, 2025, the FDA approved Ozempic for kidney disease in adults who already have type 2 diabetes and chronic kidney disease, Novo Nordisk said. The indication is to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death. It applies to the 0.5 mg, 1 mg, and 2 mg Ozempic pens. It does not apply to Wegovy’s 1.7 mg or 2.4 mg weight-loss doses.
For that kidney use, the label’s 1 mg once weekly maintenance dosage comes after at least four weeks at 0.5 mg. The shot is started at 0.25 mg weekly for four weeks to limit stomach side effects. Ozempic first gained a U.S. glucose indication in 2017 and a heart-event indication in 2020 for adults with type 2 diabetes and known heart disease. The prescribing information, revised May 2026, still warns that diarrhea, nausea, and vomiting can dehydrate a patient and lead to acute kidney injury.
THE PATH TO THE KIDNEY LABEL
- 2017: The FDA first approves Ozempic to lower blood sugar in adults with type 2 diabetes.
- 2020: A second indication covers major heart events in adults with type 2 diabetes and known heart disease.
- October 2023: FLOW’s planned interim analysis triggers an early stop for efficacy after about 570 primary events.
- July 11, 2024: FLOW is published, with 3,533 people followed a median 3.4 years and a 24% lower primary-event risk.
- January 28, 2025: The FDA adds the kidney-failure and heart-death indication for Ozempic in type 2 diabetes with chronic kidney disease.
- October 1, 2026: REMODEL reports MRI, biopsy, and gene data from 106 people treated for 52 weeks.
Richard E. Pratley, medical director at AdventHealth Diabetes Institute in Orlando and a FLOW co-chair, put the approval in clinic language rather than scan language.
A large portion of patients I treat experience serious kidney complications and comorbidities, with some even requiring dialysis.
Richard E. Pratley, MD, FLOW trial co-chair, Novo Nordisk statement
Patients Stacked Semaglutide on Older Kidney Drugs
REMODEL was not a test of semaglutide alone in untreated kidneys. RAS blockade was nearly universal. SGLT2 inhibitors, now first-line in much of nephrology, were already used by 39.6% of the full cohort and 54.5% of the biopsy group. The kidney signal appeared on top of those drugs, which is how the shot will be used if it is used at all.
KDIGO’s 2024 chronic kidney disease guideline still places SGLT2 inhibitors as first-line therapy for most people with CKD who meet eGFR and albumin cutoffs, with or without diabetes. A 2025 KDIGO commentary kept a long-acting GLP-1 RA after SGLT2 inhibitors (and metformin) for adults with type 2 diabetes and CKD who miss glucose targets or cannot take those drugs, and said an updated guideline would take FLOW head-on. Finerenone, a nonsteroidal mineralocorticoid receptor blocker, is a separate add-on when albumin stays high.
THE USUAL ORDER IN DIABETIC KIDNEY DISEASE
- RAS blocker: An ACE inhibitor or ARB remains background therapy; 99.1% of REMODEL was already on one.
- SGLT2 inhibitor: Guideline first-line for many CKD groups, including people without diabetes when eGFR and albumin allow.
- GLP-1 receptor agonist: Semaglutide 1 mg weekly now carries a dedicated kidney-and-heart-death indication in type 2 diabetes with CKD.
- Nonsteroidal MRA: Added when albuminuria stays high in type 2 diabetes and CKD, a different pathway from GLP-1.
FLOW itself ran with only about 16% of people on an SGLT2 inhibitor at baseline, a lower share than REMODEL, because those drugs spread after FLOW was designed. Serious adverse events in FLOW were 49.6% with semaglutide and 53.8% with placebo. Stomach effects remain the common reason people stop, and the label’s dehydration warning is the kidney-specific safety note, not a claim that the drug scars the organ.
Thirty-Three Biopsies and the Reversal Claim
The popular reading is that a weight-loss shot repairs kidneys. REMODEL’s own primary scans did not show that. Secondary MRI, albumin, arteriole intima, and endothelial gene programs did. The biopsy set was 33 people. Spatial maps used 13 paired samples. There was no multiplicity adjustment across the MRI and clinical secondaries, and the authors caution that exploratory P values should be read with that in mind. Mediation analysis, which would test whether fat loss or endothelial reprogramming caused the albumin drop, was not done.
WHAT WE KNOW
- The population: Adults with type 2 diabetes and CKD, already on RAS blockade, treated for 52 weeks with semaglutide 1 mg weekly.
- The lab signal: UACR 40% lower than placebo, with higher 24-hour creatinine clearance.
- The tissue signal: Lower resistive index, less diseased-arteriole intima, quieter immune-endothelial chatter in the glomerulus.
- The outcomes backdrop: FLOW’s 24% lower composite of kidney decline, kidney failure, or kidney or heart death in 3,533 people.
WHAT IS UNCONFIRMED
- Reversal of scarring: ADC suggested slower fibrosis; the coprimary inflammation map did not change, and histology was a small subgroup.
- Nondiabetic CKD: Neither FLOW nor REMODEL enrolled it, and the FDA kidney indication does not cover it.
- Cause versus companion: Weight, sugar, perirenal fat, and endothelial genes all moved; which one carries the kidney benefit is unproven.
- Dialysis counts: Kidney-replacement events in FLOW did not fall on their own; the composite did.
Tuttle said patients’ damaged kidneys showed clear signs of repair. The honest remainder is smaller than that sentence. In diabetic kidney disease, a year of weekly semaglutide can quiet the filter’s immune chatter and cut albumin 40%, and that is the group the U.S. label already names. It is also the group that still fills most of the path to kidney failure. REMODEL mapped a possible route. It did not close the case that chronic kidney disease, as a whole, can be reversed.
Frequently Asked Questions
Is Ozempic Approved for Kidney Disease Without Diabetes?
No. The January 28, 2025 kidney indication is limited to adults who have both type 2 diabetes mellitus and chronic kidney disease. FLOW and REMODEL enrolled that pair of conditions, and the prescribing information does not extend the kidney-failure claim to people whose CKD has another cause.
What Dose of Ozempic Is Used for Kidney Protection?
The label’s kidney maintenance dose is 1 mg injected once weekly after at least four weeks at 0.5 mg. Treatment starts at 0.25 mg weekly for four weeks, a step meant to blunt nausea and vomiting, and the 2 mg pen is not the dose studied for kidney outcomes in FLOW or REMODEL.
Can Semaglutide Cause Kidney Injury?
The Ozempic label warns that diarrhea, nausea, and vomiting may cause volume depletion and acute kidney injury, and it tells clinicians to watch kidney function when those stomach effects persist. That warning sits beside the FLOW benefit and is a hydration and monitoring problem, not a finding that the drug scars kidney tissue.
Does Wegovy Carry the Same Kidney Indication?
No. The kidney indication applies to Ozempic 0.5 mg, 1 mg, or 2 mg and does not include Wegovy 1.7 mg or 2.4 mg, which remain weight-management products with a different dose ladder. Patients using Wegovy for obesity do not pick up FLOW’s kidney claim by default.
Disclaimer: This article is news reporting and analysis of published trial data and a U.S. drug label, and it is for information only. It is not medical advice, a treatment recommendation, or a substitute for care from a physician, nephrologist, or other qualified clinician who knows a reader’s diagnoses, other medicines, and laboratory results. Anyone considering semaglutide, stopping it, or changing diabetes or kidney therapy should talk with that clinician first, because dose, side effects, and eligibility depend on the individual. Figures, trial results, and approval status reflect the papers, the Ozempic prescribing information, and public health data cited here and can change if labels, guidelines, or later studies are updated.
-
NEWS2 months agoAI Server Boards Put Everyday Circuit Materials on Allocation
-
NEWS3 months agoGlacier Collapse Buried Nepal’s Hydropower Workers in Tunnels
-
NEWS3 months agoCongo’s Bundibugyo Outbreak Outruns the Licensed Ebola Shots
-
NEWS3 months agoPennsylvania Measles Deaths Follow a Long Slide in Coverage
-
NEWS3 months agoCISA’s Known Exploits Still Come From 2007-Era Bugs
-
NEWS3 months agoTexas Judge Freezes the SEC Eligibility Ban for 41 Athletes
-
NEWS3 months agoGermany Can Miss Its 2026 Climate Cap Without Penalty
-
NEWS3 months agoFDA Approves XFG COVID-19 Vaccines Without a CDC Vote
